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Abstract 
The aim of this work is to formulate Ketorolac tromethamine in a new 
ocular in situ hydro gel delivery system. Two polymers; Chitosan and 
Carbopol 940 were used in different concentrations for the preparation 
of the in situ hydro gels, all formulations exposed to visual examination, 
pH measurement, in-vitro release, rheological study, stability study, and 
in-vivo anti-inflammatory effect study on the inflamed eye of rabbits. 
Results showed that all formulations were clear and showed pH within 
the acceptable range, Chitosan 0.5%w/v gives the highest release rate, 
all formulae exhibited pseudoplastic flow with a thixotropic behavior, 
stability study showed that rate of drug degradation followed first order 
kinetics and 0.5% Chitosan based formula showed longer shelf life 
(2.532 year), the percent of unhealed ulcers of the inflamed eye of 
rabbits was 17.5% for 0.5% Chitosan in situ hydro gel compared to 55% 
for Acular eye drop (positive control). Statistical analysis of the data 
revealed significance difference between the tested formula and control 
solution at p <0.05. So this system that combines the advantages of both 
solutions and gels, such as accuracy and facility of administration of the 
former and prolonged residence time of the latter, also enhances the 
healing rate of Ketorolac tromethamine in ulcerative rabbit's eye 
compared to ocular eye drops. 
Keywords: Ketorolac Tromethamine; In situ gel; Chitosan; Corneal 
ulcer; Hydro gel 
Introduction 
Drugs are commonly applied to the eye for a 
localized action on the surface or in the interior of 
the eye [1]. A major problem in ocular therapy is 
to attain an optimal drug concentration at the site 
of action. Poor bioavailability of drugs from 
ocular dosage form is mainly due to the 
precorneal loss factors which include tear 
dynamics, non-productive absorption, transient 
residence time in the cul-de-sac, and the relative 
impermeability of the corneal epithelial 
membrane [2-3]. Due to these physiological and 
anatomical constraints, only a small fraction of 
the administered drug, (effectively 1% or even  
 
less of the instilled dose) is ocularly absorbed. [4-
5].  
 
In order to overcome the problems of 
conventional ocular therapy, newer delivery 
systems are being explored. Various approaches, 
like viscosity enhancement, use of 
mucoadhesives, particulate drug delivery, 
vesicular drug delivery, prodrugs, and other 
controlled systems, like ocuserts, are being 
explored [2-3, 6-7].  
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Ketorolac is a non-steroidal agent with a 
powerful analgesic and moderate anti-
inflammatory activity, widely used in the 
management of both moderate and severe pain [8, 
9], Ketorolac is applied topically in the 
management of seasonal allergic conjunctivitis, 
postoperative ocular pain and inflammation [10]. 
It is nonirritating to the eye at 0.5% w/v 
concentration [11].  
 
The use of preformed hydrogels still has 
drawbacks that can limit their interest for 
ophthalmic drug delivery or as tear substitutes, 
they do not allow accurate and reproducible 
administration of quantities of drugs and, after 
administration; they often produce blurred vision, 
crusting of eyelids, and lachrymation. A new 
approach is to try to combine advantages of both 
solutions and gels, such as  accuracy and facility 
of administration of the former and prolonged 
residence time of the latter, thus in situ hydrogels 
can be instilled as eye drops and undergo an 
immediate gelation when in contact with the eye 
[12-13].  
 
Chitosan shows sol to gel transformation when 
the pH exceeds 6.2 due to the neutralization of 
chitosan amine groups is obtained by alkaline 
deacetylation of chitin, which is one of the most 
abundant polysaccharides in nature found in 
various organisms including the cell walls of 
fungi and exoskeletons of arthropods such as 
crabs, shrimps and insects [14]. It is cationic, 
nontoxic, biocompatible and biodegradable. In 
addition, chitosan has mucoadhesive properties 
[15].  
Carbopol is a polyacrylic acid (PAA) polymer, 
which shows a sol to gel transition in aqueous 
solution as the pH is raised above its pKa of 
about 5.5 [16], is widely used in ophthalmology 
to enhance precorneal retention to the eye [12]. 
Carbopol offers the advantage of exhibiting 
excellent mucoadhesive properties when 
compared with other polymers.  
 
The formulation of a stable dosage form is 
essential for the patients' safety and drug efficacy. 
The physicochemical parameters, such as the 
presence of additives as well as the storage 
conditions, which may affect the stability of 
drugs, have received considerable attention in the 
field of pharmaceutics [17]. 
 
The purpose of stability testing is to provide 
evidence of how the quality of a drug substance 
or drug product varies with time under the 
influence of various environmental recommended 
storage conditions, retest periods and shelf-lives 
to be reestablished [18]. 
 
So, the aim of this work is to formulate Ketorolac 
tromethamine in a new ocular in situ hydro gel 
delivery system using Chitosan and Carbopol 940 
at different concentrations. The prepared in situ 
hydro gel formulations will be fully evaluated; 
also In vivo anti-inflammatory effect on the 
inflamed eye of rabbits for the prepared 
formulations will be studied. 
 
Material and Methods 
  
Materials 
 
Ketorolac Tromethamine [ELAMRIA Company, 
Alexandria, Egypt]. Carbopol 940 [Goodrich 
Chemical Company, Ohio, USA], Cellulose 
nitrate membrane filter, diameter pore: 0.45 µm 
[Albet Company, Spain], Chitosan [Nantong, 
China]. Triethanolamine [Merck, Germany] 
 
Methods 
 
Preparation of Ketorolac Tromethamine in-
situ forming hydro gels: 
  
Using Chitosan 
Chitosan solution was obtained by dissolving the 
required amount of chitosan in 10 mls of 0.1 N 
HCl under mechanical stirring at room 
temperature. This solution was cooled down to 
5ºC using an ice bath and 2 g of Glycerol (at 5 º 
C) was added as gelling agent. The calculated 
amounts of Ketorolac Tromethamine (KT) and 
NaCl were added to prepare isotonic 5mg/ml 
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drug solution and the pH was then adjusted to 6.2 
by dropwise addition of diluted NaOH (at 5 º C). 
Finally, cold water was added to obtain a total 
mass of 20 gm. The final preparations contained 
10% (w/w) of a gelling agent [19]. Chitosan 
Solutions were prepared at concentrations of 
0.25, 0.5 and 1% (w/w) before pH adjustment. 
 
 
Using Carbopol: 
The weighed amount of carbopol 940 was 
gradually sprinkled on 100ml of 0.5% drug 
solution and stirred with mechanical stirrer at 
high speed until no lumps was observed. Stirring 
speed was then reduced to break the foam. 
Finally pH of the product was adjusted to 5.5 
using triethanolamine. Carbopol Solutions were 
prepared at concentrations of 0.1 and 0.2% (w/v). 
  
Evaluation of the prepared Ketorolac 
Tromethamine in-situ forming hydro gels: 
 
The prepared formulations were evaluated as 
follows: 
Visual Examination:  
The general appearance (clarity) of the 
formulations was examined visually. 
 
pH Measurement:  
The pH of the prepared formulations was checked 
by using pH-meter. 
  
Determination of Drug Loading Capacity:  
The drug loading capacity (drug content) was 
determined by diluting 1gm of the prepared 
formulation to 100 ml with simulated tear fluid 
[STF] pH 7.4 then stirring with magnet until 
dissolved. Aliquots of 5 ml were withdrawn and 
further diluted to 25ml with STF. Ketorolac 
tromethamine concentration was determined 
spectrophotometrically at λmax 322 nm. 
 
Determination of Gelling Capacity: 
In order to identify the compositions suitable for 
use as in situ gelling systems, gelling capacity of 
the prepared formulations was evaluated. The 
gelling capacity was determined as follows: the 
prepared in situ gelling systems were mixed with 
freshly prepared STF in the ratio of 25: 7 
respectively (application volume 25 µm, normal 
volume of tear fluid in the eye is 7 µl) at 35ºC± 
0.5. Gelation was assessed by visual examination 
[20]. The time for gelation & the time taken for 
the formed gel to re- dissolve were recorded. The 
composition of artificial tear fluid was sodium 
chloride 0.670 g, sodium bicarbonate 0.200 g, 
calcium chloride·2H2O 0.008 g, and purified 
water q.s.100 g [21]. 
  
In-vitro release of Ketorolac Tromethamine 
from the prepared in-situ hydro gel 
formulations: 
A glass cylindrical tube (2.5 cm in diameter and 6 
cm in length) containing the formulae to be tested 
was attached instead of the basket of the 
dissolution apparatus and tightly covered with a 
semi permeable membrane (0.45 µm pore size), 
The cylindrical tube was dipped in a 500 ml 
simulated tear fluid (PH 7.4), the release study 
was carried out at 34ºC ± 0.5, [the temperature of 
the eye] [22], according to predetermined time 
regimen, aliquots of 5 ml were withdrawn and 
further diluted to 25 ml with STF. Ketorolac 
tromethamine concentration was determined 
spectrophotometrically at λmax 322 nm; the 
results were the mean values of three runs. 
 
Kinetic analysis of the release data of Ketorolac 
Tromethamine from the prepared in-situ hydro 
gel formulations: 
The release data were analyzed using the linear 
regression according to: 
Zero Order Kinetics: Ct = C0 - Kt 
First Order Kinetics: Log Ct = Log C0 – kt/2303 
And also according to the simplified Higuchi 
diffusion model [23] 
                                     Q/A = 2C
 0 (A/2n) 1/2 t1/2 
The correlation coefficient (r) was determined in 
each case. 
 
 
 
Measurement of viscosity of the prepared in-situ 
hydro gel formulations:  
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The viscosity determination of prepared 
formulations was carried out using Brookfield 
Viscometer with spindle 52. Viscosity of samples 
was measured at different angular velocities. A 
typical run comprised changing angular velocity 
from (10 to 100) rpm with equal wait for each 
rpm. The angular velocity was reversed (100 to 
10 rpm). The rheological parameters of different 
formulations were studied. 
  
Stability study of Ketorolac Tromethamine in 
the prepared in-situ hydro gelling systems:  
 
On the basis of the previous evaluation studies of 
the prepared Ketorolac Tromethamine 
formulations; F1b (0.5%Chitosan) was selected 
to undergo further stability studies. The selected 
formulation was stored in dark place at controlled 
room temperature (25ºC ± 2) for one year to 
detect any change in its characteristics which may 
affect efficacy or suitability for use over their 
shelf life. 
At predetermined time intervals, samples were 
withdrawn and examined physically for any 
changes and chemically for its Ketorolac 
Tromethamine content using the HPLC stability 
indicating assay. The stability study includes both 
physical and chemical stability. 
  
Physical stability of the selected Ketorolac 
Tromethamine formulation which include: 
Visual Examination - pH Measurements - 
Determination of The Gelling Capacity - In-vitro 
Release - Kinetic Analysis of the Release Data of 
Ketorolac Tromethamine from its Different 
Formulations after Storage for 12 Month. -
Rheological Evaluation. 
  
Chemical stability of the selected Ketorolac 
Tromethamine formulation. 
Samples were analyzed for the percent remaining 
of Ketorolac tromethamine using HPLC stability 
indicating assay at time intervals of 0, 2,4, 6,8,10 
and 12 months. 
  
In-Vivo anti-inflammatory effect of Ketorolac 
Tromethamine on the inflamed eye of rabbit:  
A group of five male rabbits (1.5-2 kg) was 
considered in this work, two drops of 0.4% 
solution of Oxybuprocaine HCl were instilled 
onto each rabbit's eye as a local anesthetic. One 
to two minutes post instillation; eight 
inflammatory areas (ulcers) were induced in the 
epithelium of the cornea of each eye, away from 
the pupil, using a thermal technique. The ulcers 
had a circular shape (2mm diameter) and reached 
in depth of corneal epithelium. This was 
ascertained by the instillation of fluroescein 
sodium solution (0.2%). Since, Fluroescein does 
not stain tissue unless the epithelium is disrupted; 
the inflamed areas develop a green fluorescence. 
The absence of green color was thus taken as a 
criterion of ulcer healing. One drop of a sterile 
ciprofloxacin eye drops (0.3%) was instilled into 
each eye. For each rabbit one eye was considered 
as a test and the other eye as a control. The 
control treatment involved instillation of one drop 
of ciprofloxacin solution every morning 
throughout the observation period. The test 
treatment involved the instillation of one drop of 
ciprofloxacin solution followed by one drop of 
the Ketorolac tromethamine solution (Acular eye 
drop) as a positive control or the formula F1b 
(0.5% Chitosan) every morning throughout the 
observation period which extended for 12 days. 
The data of corneal inflammation healing time 
were subjected to statistical analysis according to 
student t-test. 
 
 
Results and Discussion 
  
Evaluation of the prepared Ketorolac 
Tromethamine in-situ hydro gels: 
According to the results listed in table (1), clarity 
of all prepared formulations was found to be 
satisfactory. The pH was within acceptable range 
(from 5.5 to 6.5) and hence would not cause any 
irritation upon administration on to the eye. 
Ideally, the ophthalmic preparations should have 
possessed the pH in the range of 4.5 – 11 [24].  
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Table 1: Results of different evaluations studies applied on the prepared KT in-situ hydro gel formulations at 
different polymer concentrations 
 
 
Formula 
Number 
Composition Appearance 
(clarity) 
pH 
Mean ± SD 
Drug Content 
(mg/ml) 
Mean ± SD 
Polymer 
type 
Polymer 
Conc. 
F1a Chitosan 0.25 Clear 6.2±0.006 98.45±0.014 
F1b Chitosan 0.50 Clear 6.2±0.010 99.43±0.025 
F1c Chitosan 1.00 Clear 6.2±0.008 100.5±0.015 
F2a Carbopol 0.10 Clear 5.5±0.000 101.3±0.006 
F2b Carbopol 0.20 Clear 5.5±0.014 99.87±0.020 
 
 
 
Percent drug content in all formulations was 
found to be within the acceptable pharmacopeial 
range of 98.35 to 101.32% indicating uniform 
distribution of drug [25]. 
 
Determination of gelling capacity: 
 
Results listed in table 2 showed that formulae F1a 
and F2a, gelled after a few minutes, dissolved 
rapidly (unacceptable formulations). But 
Formulae F1b and F2b, gelled instantaneously 
(less than a minute), and retained their 
consistency for a few hours on contact with STF 
(acceptable formulations). F1c, gelled 
instantaneously (less than a minute) and remained 
for an extended period (unacceptable 
formulations) as this may cause irritation to the 
eye upon application. These results can be easily 
correlated with the polymer concentration into 
the prepared in situ hydrogel formulations as 
follows, formulations of low polymer 
concentration (low viscosity) showed low gelling 
capacity (sign+) and formulations of moderate 
polymer concentration (moderate viscosity) 
showed acceptable gelling capacity 
(sign++),While the formulations of high polymer 
concentration (high viscosity) showed high 
gelling capacity (sign+++). 
 
 
 
 
Table 2: Results of gelling capacity study applied on 
the prepared KT in-situ hydro gel formulations at 
different polymer concentrations. 
 
Formula 
Number 
Gelling 
Capacity 
F1a + 
F1b ++ 
F1c +++ 
F2a + 
F2b ++ 
 
Notice:   +: Gels after few minutes and rapidly dissolves. 
            ++: Immediately gels and remains for few hours. 
+++: Immediately gels and remains for an 
extended time period. 
 
In-vitro release of Ketorolac Tromethamine 
from different formulations: 
 
Figure 1 shows that the percentage of drug 
released after 320 min from F1a, F1b, and F1c 
was 82.9%, 77.66%, and 66.33% respectively. 
Figure (2) shows that the percentage of drug 
released after 320 min from F2a, and F2b were 
81.02%, and 74.87% respectively. 
It is clear from these results that all formulations 
showed initial burst release due to the hydrophilic 
nature of the prepared in situ gel formulations, 
slowing the release rate later on can be explained 
on the basis of the diffusion process of the drug 
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through the formula that markedly retarded due to 
increase of the its viscosity in contact with the 
release media. In other words; the release of drug 
from the prepared in situ hydro gels is inversely 
proportional to the gel strength. The results of the 
drug release study can also be inversely related to 
the polymer concentrations in the prepared 
formulae. 
 
 
 
Fig 1: In-vitro release of KT from Chitosan based 
formulations in simulated tear fluid at 34º C. 
 
 
 
 
 
Fig 2: In-vitro release of KT from Carbopol based 
formulations in simulated tear fluid at 34º C 
 
 
 
Kinetic analysis of the release data of 
Ketorolac Tromethamine from the prepared 
in-situ hydro gel formulations: 
 
The release data of KT from its different 
formulations was treated mathematically 
according to zero, first order and Higuchi 
diffusion model mechanisms. The data is 
illustrated in table (3). It is clear that the release 
of KT follows diffusion controlled mechanism. 
These results are related to the change in 
consistency of the in situ hydro gel formulae in 
contact with the release media. 
 
 
Measurement of viscosity of the prepared 
formulations: 
 
The flow behavior of the two formulations which 
showed acceptable gelling capacity [F1b, F2b] 
was described in table (4). From the data of the 
table, all formulations exhibited pseudoplastic 
flow with a thixotropic behavior. Generally 
viscosity values in the range of 15-50 cps 
significantly improve the contact time in the eye. 
Higher viscosity values are not required as it does 
not offer significant advantage and have a 
tendency to leave a detectable residue on the lid 
margin. The administration of ophthalmic 
preparation should influence as little as possible 
the pseudoplastic character of the pre-corneal 
film. Since the ocular shear rate is very high, 
ranging from 0.03 s -1 during interblinking 
periods to 4250 - 28,500 s -1 during blinking [26], 
viscoelastic fluids with a viscosity that is high 
under low shear rate conditions and low under the 
high shear rate conditions are often preferred. 
 
Physical stability of the selected Ketorolac 
Tromethamine formulation after storage for 
12 months: 
Formula F1b showed no change in clarity upon 
storage for one year. The pH showed slightly 
change but still within the acceptable range, 
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Table 3: Kinetic analysis of release data of KT from the prepared in-situ hydro gel formulations 
 
Formula Number 
Linear Regression Analysis Using Correlation 
Coefficient (r2) According to: 
Zero Order First Order Diffusion Model 
F1a 0.7338 0.8898 0.9322 
F1b 0.8059 0.9213 0.9677 
F1c 0.8702 0.9295 0.9911 
F2a 0.7397 0.8774 0.9361 
F2b 0.7749 0.8761 0.9404 
 
 
Table 4: Results of the rheological study applied on the selected KT in-situ hydro gel formulations. 
 
Formula 
Number 
Minimum 
Viscosity (c.p.) 
Maximum 
Viscosity (c.p.) 
Furrow’s 
Constant (N) Flow Behavior 
F1b 75.4 30.2 1.633 Pseudoplastic 
F2b 250.5 84.06 1.749 Pseudoplastic 
 
Table 5:Results of the stability study applied on KT in-situ hydro gel formula F1b for one year. 
 
Formula 
Number 
Percentage of Ketorolac Tromethamine remained after storage for the 
following time intervals  (Month) 
0 2 4 6 8 10 12 
Fb1 100 99.42 98.72 97.95 97.42 96.61 95.84 
 
Table 6:Results of kinetic analysis of the stability data of KT in-situ hydro gel formula F1b. 
 
Formula 
Number Corr. Coeff. (r) Slope Intercept 
K 
(month-1) 
t50% 
(month) 
t90% 
(month) 
Fb1 Zero 0.9974 -0.0015 2.0004 0.003455 200.6079 30.395 First 0.9978 
 
Table 7:Number and percentage of unhealed ulcers in rabbit’s eyes after application of 0.3% Ciprofloxacin 
eye drops (negative control), Acular eye drops (positive control), and Test formula F1b after 12 days. 
 
 
Tested Formula Mean Number of Unhealed Ulcers 
Percentage of Ulcer 
Healing 
Ciprofloxacin eye drops (0.3%) 
(negative control) 7 87.5 
Acular eye drops 
(positive control) 4.4 55 
Test formula F1b 1.4 17.5 
Zaki et al. International Journal of Drug Delivery 3 (2011) 535-545 
 
 
 
542 
 
Table 8: Kinetic analysis of the results of the healing effect of Ketorolac Tromethamine on ulcerative 
rabbit’s eye 
 
 
Tested Formula 
Linear Regression 
Analysis Using Corr. 
Coeff(r) According to: Kinetic 
Order 
First Order Parameters 
Zero Order First Order Slope 
Healing 
Rate 
Constant 
[K (day-1)] 
Half Life 
t1/2 (day) 
Ciprofloxacin eye drops (0.3%) 
(negative control) 0.8689 0.8767 First -0.00465 0.0107 64.712 
Acular eye drops 
(positive control) 0.9613 0.9658 First -0.02595 0.0597 11.596 
Test formula F1b 0.9248 0.9925 First -0.06526 0.1502 4.611 
 
 
 
 
 
 
 
Table 9: Statistical analysis of the difference between Control and Acular and between Test Formula (0.5% 
Chitosan solution) and Acular eye drops {With Regard to the Number of Residual Ulcers} According to t-
test Analysis 
 
 
Days 
Acular with control 0.5%Chitosan with Acular 
t p t p 
3 0.632456 N.S 5.879747 0.001 
5 0.2886751 0.02 6 0.001 
7 6.957011 0.001 5.879747 0.001 
10 6.5 0.001 6 0.001 
12 6.5 0.001 8.660254 0.001 
N.S.: Non significant   P: level of significance 
 
 
 
also the gelling capacity showed no change. 
Regarding drug release studies, Fig (3) shows 
that there storage of the prepared in situ hydro gel 
formulae did not affect the release of the drug. 
The release profile of Ketorolac tromethamine 
from different formulations still follows Higuchi 
diffusion mechanism. 
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Chemical stability of the selected Ketorolac 
Tromethamine formulation 
 
The results of the stability study of the drug in the 
prepared formulations were presented in table (5) 
which illustrated that percentage of KT remained 
in formula F1b after storage for 12 month was 
found to be 95.84%. Kinetic analysis of the 
stability data revealed that the degradation 
followed first-order kinetics, as presented in 
Figure (4).The predictive shelf life was calculated 
according to the order equation, which states that: 
t90 = 0.105/ K25 and results showed that, F1b 
possessed a predictive shelf life of 2.532 years as 
shown in table (6). 
 
 
 
 
 
Fig 3: In-vitro release of KT from fresh and stored in-
situ hydro gel Formula (F1b) in simulated tear fluid at 
34ºC 
 
VIII-Performance of Ketorolac Tromethamine 
on the healing of ulcerative cornea of rabbit 
eye: 
 
The anti-inflammatory effect of Ketorolac 
tromethamine was determined through the rate 
and extent of healing of inflamed tissue in the 
ulcerative areas in the cornea of rabbits. The 
vehicles used were negative control 
(ciprofloxacin solution), positive control (Acular 
eye drops) and the test formula F1b (0.5% 
Chitosan). The period of observation was 12 
days. At the end of the observation period the 
percent of unhealed ulcers were 87.5%, 55% and 
17.5% for negative control, positive control and 
test in situ hydro gel formula F1b respectively as 
shown in table (7). 
 
Table (7) also shows the healing rate of the 
corneal ulcers for negative control, positive 
control and test formula F1b. According to the 
results of kinetic analysis of the healing data 
listed in table (8), it is obvious that the healing 
process follows first order kinetics. In the 
absence of Ketorolac tromethamine (negative 
control), the healing process proceeds very 
slowly with ulcer half life time 64.71days. 
Treatment with the test formula F1b drastically 
enhanced the healing process and the ulcer half 
life was lowered to about 4.61 days. On the other 
hand Acular eye drops (positive control) lowered 
the half life to 11.59 days when compared to 
negative control.  
Results of the statistical analysis of the healing 
data are shown in table (9), it is obvious that, 
there is a significant difference between test 
formula F1b and positive control (Acular eye 
drops) at the tested probability levels. 
 
 
 
 
 
Fig 4: A plot of log percent of Ketorolac 
Tromethamine remained in-situ hydro gel Formula 
(F1b) versus time according to first-order kinetics. 
 
 
Conclusion 
 
Formulation of Ketorolac Tromethamine in 
chitosan based in situ hydro gel form was able to 
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reach the target area, to sustain drug release in 
high therapeutic levels, to decrease frequency of 
drug administration to prolong contact time, and 
to enhances the healing rate of Ketorolac 
tromethamine in ulcerative rabbits eye compared 
to commercially available eye drops. 
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